Guardant Health, Inc.
GH
Rang in Aktien
#1098
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Aktienkurs
$157.94
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$21.19B
Veränderung (1 Tag)
-4.79%
Veränderung (1 Jahr)
141.28%
Land
US
Handel Guardant Health, Inc. (GH)
Kategorie
Healthcare
Operative Marge für Guardant Health, Inc. (GH)
Operative Marge zum October 2026 TTM: -39.75%
Laut den neuesten Finanzberichten und dem Aktienkurs von Guardant Health, Inc. beträgt die aktuelle operative Marge (TTM) -39.75%. Am Ende des Jahres 2023 lag die operative Marge bei -100.14%.
Historie der operativen Marge von Guardant Health, Inc. von 2016 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -39.75% | -33.77% |
| 2024 | -60.02% | -40.06% |
| 2023 | -100.14% | -17.31% |
| 2022 | -121.10% | 10.09% |
| 2021 | -110.00% | 23.71% |
| 2020 | -88.92% | 131.44% |
| 2019 | -38.42% | -62.53% |
| 2018 | -102.54% | -33.29% |
| 2017 | -153.71% | -11.49% |
| 2016 | -173.66% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 17.97% | -100.45% |
US
|
|
| 20.42% | -100.51% |
US
|
|
| -10.70% | -99.73% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -100.56% |
US
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.